RealFeedApp 66% to 90% of CGT production outsourced to contractors
Advances in gene editing and AI are growing the role of third-party contractors in cell and gene therapy. Industry experts estimate that 66% to 90% of CGT production is currently outsourced to external manufacturers.
- Field
- business and funding
- What they did
- Researchers note that the integration of artificial intelligence and gene editing technologies is expanding opportunities for third-party contractors in cell and gene therapy production.
- Why it matters
- This is beneficial for the industry because 66–90% of production is already outsourced to external manufacturers who lack real-world production expertise, but there are contractors with the required capabilities.
#cdmo#gene editing#cell therapy#outsourcing#ai#manufacturing
